ahlam1399
09-09-2015, 04:58 PM
BRIEF-Genmab an**unces European regulatory submission for daratumumab
* Says Janssen has submitted a marketing authorization application to European Medicines Agency for daratumumab in double refractory multiple myeloma
http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/1/rc.img (http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/2/rc.img (http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/3/rc.img (http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/3/rc.htm)
http://da.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2.img (http://da.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2.htm)
http://adchoice.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/ach.img (http://adchoice.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/ach.htm)http://pi.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2t.imghttp://pi2.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/49b23005/sc/24/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=EA60ABPmHI8:8G4K33loMvs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=EA60ABPmHI8:8G4K33loMvs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=EA60ABPmHI8:8G4K33loMvs:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=EA60ABPmHI8:8G4K33loMvs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=EA60ABPmHI8:8G4K33loMvs:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/EA60ABPmHI8
* Says Janssen has submitted a marketing authorization application to European Medicines Agency for daratumumab in double refractory multiple myeloma
http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/1/rc.img (http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/2/rc.img (http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/3/rc.img (http://rc.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/rc/3/rc.htm)
http://da.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2.img (http://da.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2.htm)
http://adchoice.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/ach.img (http://adchoice.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/ach.htm)http://pi.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2t.imghttp://pi2.feedsportal.com/r/238385465256/u/49/f/654213/c/35217/s/49b23005/sc/24/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/49b23005/sc/24/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=EA60ABPmHI8:8G4K33loMvs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=EA60ABPmHI8:8G4K33loMvs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=EA60ABPmHI8:8G4K33loMvs:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=EA60ABPmHI8:8G4K33loMvs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=EA60ABPmHI8:8G4K33loMvs:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/EA60ABPmHI8